FDA approves Qelbree label update for ADHD treatment
ROCKVILLE, Md. - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company specializing in CNS diseases with an impressive 89% gross profit margin, has announced the FDA approval of a ...
Nasdaq14d
Supernus Pharmaceuticals Announces FDA Approval for Updated Qelbree Label Including New Pharmacodynamic Data and Lactation Information
The mechanism of action of Qelbree, though unclear, is thought to be through inhibiting the reuptake of norepinephrine. Additionally, the updated label now includes new lactation data for ...
Supernus announces U.S. FDA approved an update for label for Qelbree
Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has approved an update for the label for Qelbree to ...
SUPN stock soars to 52-week high, hits $39.38 amid growth
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) stock has reached a new 52-week high, touching $39.38 as the company continues to show robust performance in the pharmaceutical sector. According to ...
Investing14d
FDA approves Qelbree label update for ADHD treatment
The new information in Section 12.2 of the label details Qelbree's partial agonist ... is thought to contribute to the drug's mechanism of action, which primarily involves inhibiting ...